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Abstract
Background: Obesity is one of the main risk factors of non-communicable diseases (NCDs) worldwide, especially in
sub-Saharan Africa. The use of Cyproheptadine increases body weight and the risk of becoming obese. The aim of
this study is to determine the prevalence of Cyproheptadine misuse in the Kinshasa population and to describe its
characteristics.
Methods: A cross-sectional study was conducted in two town sectors of Kinshasa, Democratic Republic of Congo
(DRC), over a 4 month period (May 2011 to August 2011). Data from 499 participants, aged between 13 and
55 years were collected and analyzed. Mean and standard deviation were used for quantitative variables and
frequency and percentage for categorical variables. In order to determine the relationship between socio-
demographic status and Cyproheptadine use the Chi-square test was conducted. Student’s t-test was used to
compare means age of Cyproheptadine users and non-users. Logistic regression was used to determine predictors
of Cyproheptadine use. A p-value of <0.05 was considered statistically significant.
Results: Overall, 499 participants were enrolled (352 females, 147 males, mean age ± standard deviation 24.9 ±
9.7 years) in the study. The majority of the study participants (72.9 %) had used Cyproheptadine as an appetite
stimulant. Females were 11 times more likely to use Cryproheptadine (OR = 11.9; 95 % CI: 7.1–20.1) than males.
People aged between 36 and 55 were three times less likely to use Cryproheptadine (OR = 0.3; 95 % CI: 0.2–0.8)
compared to teenagers. More than half of the participants (69.0 %) declared to take daily Cyproheptadine. Half of
the study participants (50.0 %) used Cyproheptadine for more than a year and also declared to combine it with
Dexamethasone (87.6 %).
Conclusion: This study shows that the Kinshasa population is significantly misusing Cyproheptadine and is highly
exposed to its risk, including obesity.
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Background
The World Health Organization (WHO) estimates that,
within the next few years, non-communicable diseases
(NCDs) will become the principal global causes of mor-
bidity and mortality worldwide [1]. Obesity is among the
main risk factors of NCDs such as cardiovascular dis-
eases (CVDs), including arterial hypertension, Type-2
Diabetes Mellitus, and metabolic syndrome; chronic kid-
ney disease, osteoarthritis and cancers [2–4]. Its preva-
lence worldwide has doubled during the past 30 years,
females being more obese than males [5].
In sub-Saharan African (SSA) countries, obesity has
also become an important public health problem. This is
mainly due to the changing lifestyle of the population in
relation to urbanization [6, 7]. The study by Dalal et al.
on NCDs in SSA reported a range of obesity prevalence
between 0.4 and 41 % [8]. This wide range of propor-
tions can be explained by the study methods used as
well as the population studied. During 2007, the preva-
lence of obesity in the DRC was estimated to be 12.2 %
for males and 13.3 % for females [9]. Studies carried out
in the DRC showed that obesity was a significant pre-
dictor of mortality among hypertensive patients and a
significant predictor of chronic kidney diseases [10, 11].
This shows that obesity is a major public health issue in
the country. Therefore, knowledge of each risk factor
leading to obesity is important in managing modifiable
NCDs risk factors.
Several factors have been reported as risk factors of
obesity. These include genetic predisposition, diet, phys-
ical activity, gender, cultural norms, and physical envir-
onment [3]. The most challenging is that several African
societies do not recognize obesity as a health problem,
but as a display of social well being and beauty [12–14].
For example, a study conducted in a multi-ethnic Carib-
bean population showed that overweight African women
were more likely to be satisfied with their body image
than non-African overweight women [15]. It is reported
too that overweight and obese African women do not
consider themselves as such, thereby reducing the likeli-
hood of them attempting to lose weight [16].
In Kinshasa, a new phenomenon named/known as the
“C4 phenomenon”, which means that the use of Cypro-
heptadine for weight gain and for obtaining a “roundness
physical appearance,” has been promoted among the
general population. C4 is a commercial name for Cypro-
heptadine, a first-generation antihistamine with anti-
serotonergic activity indicated for treatment of rhinitis,
conjunctivitis and urticaria [17] but which has appetite
stimulation as a side effect thereby increasing food in-
take and inducing weight gain. It is by using this side ef-
fect that Cyproheptadine is prescribed in the treatment
of anorexia, cachexia, and severe malnutrition. The ef-
fect of Cyproheptadine on weight gain has been
confirmed in many studies. For example, a randomized
controlled trial by Couluris et al. of the effect of Cypro-
heptadine hydrochloride on weight in children with can-
cer/treatment-related cachexia found a mean weight
gain of 2.6 Kg after 4 weeks of treatment with Cypro-
heptadine among patients with cachexia [18]. Interest-
ingly, several others randomized controlled trials
strengthened the effect of Cyproheptadine on weight
gain in both children and adults’ populations. These
studies reported a high average weight gain in the group
of patients receiving Cyproheptadine than in the placebo
group [19, 20]. However in Kinshasa, this molecule is
abusively promoted, labeled and provided as an appetite
stimulating drug and is sold to people who desire to gain
weight, even without medical prescription, in order to
have “roundness physical appearance”. This inappropri-
ate use of Cyproheptadine can lead unconsciously to
obesity while users aim for roundness. Currently no
study has been carried out for describing this non-
communicable disease risk behaviour in the Kinshasa
population. This study aims to determine the prevalence
of the misuse of Cyproheptadine in the Kinshasa popula-
tion and to describe its characteristics.
Methods
Study design and sample
Between May and August 2011 a cross-sectional study
was carried out in two town sectors of Kinshasa. These
town sectors were selected purposively because of their lo-
cation in the central part of Kinshasa and their population
behaviour to the up-to-date fashion. Thereafter, a multi-
stage sampling was used for identifying study participants.
The first stage involved selection of three neighborhoods
in each town sector using a simple random sampling tech-
nique. In the second stage, in each selected neighborhood
three streets were selected using also a simple random
sampling technique. In the streets by systematic random
sampling the household was selected and there all mem-
bers of household aged between 13 and 55 years were en-
rolled. A total of 499 participants were surveyed. The
study protocol was approved by the Internal Review Board
of the University Of Kinshasa Faculty Of Pharmacy
(Protocol approval number 05/2011). A written informed
consent according to the Helsinki declaration II was ob-
tained from all the study participants. For participants
younger than 16 years of age, signed informed consent of
parents were additionally obtained. Confidentiality was
maintained by not using participants’ names in the ques-
tionnaire. A face-to-face interview using a structured
questionnaire was used for data collection.
Study variables
The content of the first part of the questionnaire included
socio-demographic variables (gender, age, education level,
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and marital status); followed in the second part by the de-
scription of Cyproheptadine use (duration and frequency
of use; reasons of use; sources of recommendation and
procurement methods; mode of administration and the
combination drugs used with Cyproheptadine). In the
third part of the questionnaire, knowledge of the side ef-
fects of Cyproheptadine and users’ satisfaction were mea-
sured. The use of Cyproheptadine was measured by
participants self-reported. In this study, the misuse of
Cyproheptadine is definedas its use for gaining weight and
having a roundness physical appearance and not for aller-
gia, real anorexia, severe malnutrition or cachexia.
Misusers were those participants, at the time of the study,
who declared that they were currently using or who had
ever used it within the past 6 months for that purpose.
Statistical analysis
Statistical analyses were performed using the statistical
package for social sciences (SPSS) of the University of
Kinshasa version 20.0. Mean and standard deviation
were used for quantitative variables and frequency and
percentage for categorical variables. In order to deter-
mine the relationship between socio-demographic status
and Cyproheptadine use Chi-square test was performed.
Student t-test was used to compare means age of Cypro-
heptadine users and non-users. Logistic regression was
used to determine predictors of Cyproheptadine use. A
p-value of <0.05 was considered statistically significant.
Results
Characteristics of the study participants and frequency of
Cyproheptadine use
A total of 499 participants were enrolled in the study, the
response rate was 100 %. There were 352 females (70.6 %)
and 147 males (29.4 %). Participants had a mean age of
24.9 years and a standard deviation of 9.7 years. As shown
in Table 1, the majority of the study participants (72.9 %)
were currently using or had used within the past six
months Cyproheptadine as an appetite stimulant. The
misuse of Cyproheptadine was significantly associated, as
shown in Table 1, with sex, females (88.9 %) used more
Cyproheptadine than males (34.7 %) (chi-square = 154.5,
df = 1); with age (participants aged 13–19 (77.8 %) used
more Cyproheptadine than those aged 36–55 (43.5 %))
(chi-square = 33.2, df = 3); with educational level (partici-
pants with no educational level (94.9 %) used more than
Table 1 Cyproheptadine use and sample characteristics, n (%)
Variables Cyproheptadine use n = 499 p
Users (n = 364) Non users (n = 135)
Sex <0.001a
Male 51 (34.7) 96 (65.3)
Female 313 (88.9) 39 (11.1)
Total 364 (72.9) 135 (29.1)
Age (years) <0.001a
13–19 147 (77.8) 42 (22.2)
20–24 70 (82.4) 15 (17.6)
25–35 120 (73.6) 43 (26.4)
36–55 27 (43.5) 35 (56.5)
Highest educational level 0.008a
No education, preschool 37 (94.9) 2 (5.1)
Primary 118 (75.6) 38 (24.4)
Secondary 192 (69.1) 86 (30.9)
Higher 17 (65.4) 9 (34.6)
Current marital status 0.018a
Never married 165 (79.3) 43 (20.7)
Currently married 176 (67.7) 84 (32.3)
Formerly, ever married 23 (74.2) 8 (25.8)
Age (mean ± SD) Users (n = 364) Non users (n = 135) p
Male 23.88 ± 7,91 29.64 ± 12.42 0.003b
Female 23.70 ± 8.98 23.74 ± 6.37 0.975b
aChi2 test
bt test
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participants with higher level (65.4 %)) (chi-square = 12.9,
df = 2) and current marital status (participants who were
currently married (67.7 %) used less than these who were
never married (79.3 %) (Chi-square = 7.9, df = 2). The re-
sults of multivariate analysis are shown in Table 2. All sta-
tistically significant variables identified in the univariate
analysis were included in the model which found two vari-
ables independently associated to misuse of Cyprohepta-
dine, sex and age-groups. The model shows a statistically
significant independent association between sex and the
misuse of Cyproheptadine (wald chi-square = 87.7, df = 1),
females were eleven times more likely to use Cyprohepta-
dine (OR = 11.9; 95 % CI: 7.1–20.1) than males. This
model also shows that the independent association be-
tween age-groups and the misuse of Cyproheptadine
(wald chi-square = 7.2, df = 3). For the, people aged be-
tween 36 and 55 were three times less likely to use Cypro-
heptadine (OR = 0.3; 95 % CI: 0.2–0.8) compared to
teenagers.
Duration and frequency of Cyproheptadine use
Table 3 shows that around half of the users declared to
take Cyproheptadine for more than 12 months (50.5 %)
and 69.0 % take it that daily.
Reasons and source of recommendation of the use of
Cyproheptadine, procurement methods
Table 3 also shows that the main reason for Cyprohepta-
dine use was weight gain (284/364 (78 %). The main rec-
ommended sources of Cyproheptadine mentioned by
Cyproheptadine users were firstly, friends (48.1 %).
Health workers/pharmacists were mentioned only by
12.9 % of users. Self-prescription was the most common
procurement method (92.6 %), and only 7.4 % of users
declared to have used a medical prescription for the pro-
curement of Cyproheptadine.
Mode of administration, and the combination drugs used
with Cyproheptadine
The main mode of administration was oral (59.1 %),
followed by the anal route (40.9 %). One hundred
and thirty nine Cyproheptadine users (38.2 %) used
Cyproheptadine on its own. Two hundred and twenty
five users (61.8 %) reported to take Cyproheptadine
associated with other drugs, Dexamethasone was the
most common drug combined with Cyproheptadine
(87.6 %).
Table 2 Socio-demographic determinants of the misuse of
Cyproheptadine in Kinshasa




Female 11.9 7.1 20.1
Age groups 0.059a
13–19 1
20–24 0.556a 0.9 0.3 1.8
25–34 0.324a 0.7 0.4 1.4
35–55 0.007a 0.3 0.2 0.8
aWald Chi2 test
Table 3 Characteristics of the use of Cyproheptadine






Health workers /pharmacists 47 (12.9)
Colleagues 17 (4.7)
Others sources 41 (11.2)
Reasons of use Cyproheptadine (n = 364)
Anorexia 80 (22.0)
To gain weight 284 (78.0)
Mode of administration (n = 364)
Oral 215 (59.1)
Anal 149 (40.9)
Frequency of use (n = 364)
Daily 251 (69.0)
Weekly 45 (12.4)
Twice a week 7 (1.9)
Three times per week 8 (2.2)
Twice a month 14 (3.8)
Rarely 39 (10.7)
Duration of use (months) (n = 364)




> 12 184 (50.5)
Procurement methods (n = 364)
Medical prescription 27 (7.4)
Self-medication 337 (92.6)
Associate Cyproheptadine with others drugs 225 (61.8)
Drugs associated to Cyproheptadine (n =225)
Dexamethazone 197 (87.6)
Vitamins 28 (12.4)
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Knowledge of side effects of Cyproheptadine abuse, fear
of addiction and satisfaction
As shown in Table 4, the majority of Cyproheptadine
users (96.7 %) were aware that Cyproheptadine could
give them some side effects. Overall, 77.2 % of Cypro-
heptadine users were afraid of the addictive effect of
Cyproheptadine usage. However, the majority of users
declared to be satisfied (97.5 %).
Discussion
This study aimed to determine the prevalence of Cypro-
heptadine misuse in the Kinshasa population and to de-
scribe its characteristics. The main findings of this study
were as follows: (i) the prevalence of Cyproheptadine
misuse was 72.9 %. (ii) Cyproheptadine was used more
by females than males and the Cyproheptadine use de-
creased with age. (iii) The majority of Cyproheptadine
users reported to use Cyproheptadine on a daily basis.
(iv) Half of Cyproheptadine users had used Cyprohepta-
dine for a period over a year. (v) Self-prescription is by
far the main procurement method of Cyproheptadine by
the users. (vi) Dexamethasone was the most common
drug combined with Cyproheptadine by users.
In the Literature, we did not find any paper that dis-
cussed Cyproheptadine use in the context of this study.
In this study, then, the prevalence of Cyproheptadine
misuse will be discussed with the prevalence of others
drugs inappropriately used for increasing the body
weight, muscle mass, strength in adults and an improved
appearance. The most reported drug is androgenic-
anabolic steroid which was mostly used by athletes and
teenagers [21, 22]. The prevalence of Cyproheptadine
misuse reported by this study was high comparatively to
the prevalence of androgenic-anabolic steroid use
reported in previous studies [22–24]. The prevalence dif-
ference may be explained by the price of Cyproheptadine
which is cheaper than androgenic-anabolic steroid.
The medical prescription was less mentioned by users
as the procurement method of Cyproheptadine, it cor-
roborates with previous studies that also reported self-
prescription as the most common procurement method
of androgenic-anabolic steroid [21]. This study reported
the long term misuse of Cyproheptadine, even though
the information about the intake posology has been col-
lected, it has not been reported because of the various
pharmaceutical forms taken by users and the lack of pre-
cision in the posology. From the Literature, Cyprohepta-
dine can reportedly produce serious side effects
especially when taken in overdose; that includes halluci-
nations, convulsions, central nervous system depression
and sudden cardiac arrest [25]. Death cases were also re-
ported as a result of Cyproheptadine intoxication at a
concentration of more than 15 times that of therapeutic.
On routine daily use, Cyproheptadine may cause several
side effects, including drowsiness, tired feeling, insom-
nia, spinning sensation, blurred vision, loss of coordin-
ation, upset stomach, nausea, diarrhea, and weight gain.
Importantly, as previously described, many randomized
controlled trials have demonstrated that Cyproheptadine
can potentially induce weight gain and/or obesity [21–
24]. We believe that the users of Cyproheptadine in
Kinshasa are exposed to these risks].
It is known that a long-term corticotherapy can cause
side effects such as hyperglycemia and diabetes, oedema,
weight gain, hypertension and immune suppression [26].
In this study, the majority of Cyproheptadine users de-
clared to take Cyproheptadine associated with Dexa-
methasone. As each of these two drugs independently
induce weight gain and obesity, their combination can
potentially increased weight gain and/ or obesity, thus,
enhancing the occurrence of NCDs.
The knowledge of the side effects of Cyproheptadine
does not prevent the use of Cyproheptadine because
knowledge alone does not explain behaviour. Perception
of risk is a major component of behaviour [27]. However
human behaviour on issues such as body image is not al-
ways rational. Rationality depends on what a person
considers to be of importance, this is also proven by this
study which reported that even people with a high level
of education taking Cyproheptadine. It is well estab-
lished that females are more obese than males. A study
conducted in South Africa showed that two factors can
explain this difference in developing countries, child-
hood circumstances and adult socioeconomic status
(SES) [28]. Evidence suggests that obesity independently
increases the risk of CVD in women even in the absence
of other metabolic abnormalities [29]. Despite a higher
risk of obesity, females are more exposed to other obeso-
genic life style such as physical inactivity and sedentary
behaviour [30]. This study also found that females were
more frequent inappropriate users of Cyproheptadine
Table 4 Knowledge about side effects of misuse of
Cyproheptadine and users’ satisfaction
Variables n (%)
Knowledge of side effects of Cyproheptadine
abuse (n = 364)
Yes 352 (96.7)
No 12 (3.3)
Fear of addiction (n = 364)
Yes 281 (77.2)
No 83 (22.8)
Satisfaction (n = 364)
Yes 355 (97.5)
Not/not really 9 (2.5)
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than males. This high attraction to Cyproheptadine use
by women can be explained by the fact that African
women think that Black men find bigger women more
attractive as described by Shoneye [16]. This hypothesis
can be confirmed because our study showed that mar-
ried women used Cyproheptadine less than single
women probably because the single women will be more
constrained to want to attract men.
This study reported that the misuse of Cyproheptadine
decreases with age. Teenagers were among the age cat-
egories using more Cyproheptadine. Previous studies
showed that the teenage years is a period during which
teenagers, in order to fit their environment’s perception
of beauty, are more concerned with their body weight,
shape and size. Therefore, depending on the social con-
text and social perception of beauty, teenagers may en-
gage either in the weight loss or gain process. The
perception of their body image is a key determinant of
their dietary habits and weight management [31]. In the
Congolese context, where plumpness is perceived as/
considered a sign of beauty and wellbeing, young ladies
usually engage in obesogenic behaviour. This may ex-
plain the use of Cyproheptadine by teenagers in our
study.
In contrast with a study carried out in Accra, the cap-
ital of Ghana, less than ten percent of women reported
to try to increase their body mass by eating more foods.
This difference can be explained by the fact that the ma-
jority of women in the Ghana study (92. 2 %) reported
that they were aware of the health risk associated with
overweight and obesity and they were older than women
in this study [32].
Limitations and strengths of the study
This study has potential limitations. The two town sec-
tors selected are not representative the whole population
of Kinshasa; knowledge of the participants or their per-
ception of risk for obesity and its complications were
not assessed. Also, the effect of Cyproheptadine on
weight gain and obesity was not measured during the
study. We surmise that the best design to show this as-
sociation should be a prospective study. These issues
need to be addressed in future studies. Nevertheless, this
is the only study, to the best of our knowledge, which
has described that phenomenon among the Congolese
population of Kinshasa. Additionally, the multi-stage
sampling and the multi-centricity of our study sample
have improved the generalisability of the result.
Conclusion
This study shows that the Kinshasa population is signifi-
cantly misusing Cyproheptadine and is highly exposed to
its risk; including obesity. There is an urgent need to
educate the community on the danger of substance
abuse, such as Cyproheptadine and steroids. More pro-
foundly, every effort should be made to change the view
or concept of the community regarding obesity.
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